NR4A1 and metastatic neoplasm: Future studies should further investigate treatment sequencing and outcomes in subgroups defined by factors of clinical relevance such as hormone receptor status, metastatic status (de novo or recurrent), and treatment history prior to metastatic disease diagnosis.